BellBrook Labs Launches Transcreener cGAS Activity Assay to Accelerate Drug Discovery

New Transcreener cGAS Assay
The new Transcreener cGAMP cGAS Assay directly measures the product cGAMP, in a cGAS enzymatic reaction allowing researchers to screen vast compound libraries for novel modulators. The assay will be used to discover and develop new treatments for autoimmune diseases and cancer by targeting the cGAS-STING pathway. Madison, WI – Researchers at BellBrook Labs have
Read more
No Comments

Discovery On Target 2019 – Let’s Talk Drug Discovery

Discovery On Target 2019
  BellBrook Labs will exhibit and present posters at the upcoming Discovery On Target conference in Boston, MA. At the event BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, studying CD73 and CD39, screening for kinase inhibitors, using Transcreener for a cGAS drug discovery program, and more!
Read more
No Comments

BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases

cGAS Inhibitors Grant
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway. Madison, WI – July 2019
Read more
No Comments

Researchers from BellBrook Labs Pen Chapter in Springer’s Rho GTPases: Methods and Protocols

Rho GTPases Rho GEFs Book
New Protocol from BellBrook Labs: High-Throughput Assay for Rho GEFs Based on the Transcreener GDP Assay In this new second edition of Springer Nature’s Rho GTPases: Methods and Protocols, researchers from BellBrook Labs describe an HTS compatible method for detecting GTPase exchange factor (GEF) activity. The protocol described in chapter twelve of the book uses
Read more
No Comments

Visit With BellBrook Labs at Discovery On Target 2018

Discovery on Target 2018
BellBrook Labs will exhibit and present posters at the upcoming Discovery on Target conference in Boston, MA. At the event BellBrook will demonstrate applications for its suite of high throughput screening tools, including residence time determination, methyltransferase activity measurement, studying ectonucleotidase enzymes, screening for kinase inhibitors, and more! Discovery on Target 2018 Sheraton Boston Hotel
Read more
No Comments

NIH Awards BellBrook Labs Phase II Grant to Develop HTS Assays Targeting the cGAS-STING Pathway for Autoimmune Diseases and Cancer

Autoimmune Disease News
The National Institutes of General Medical Sciences (NIGMS) recently awarded BellBrook Labs a $1 million phase II Small Business Innovative Research (SBIR) grant to develop new assays to detect cyclic GMP-AMP (cGAMP) levels in biological samples. The assays will be used to discover, develop, and monitor new treatments for autoimmune diseases and cancer by targeting
Read more
No Comments

Meet with BellBrook Labs at SLAS 2018

  BellBrook Labs will showcase its products for drug discovery at the Society for Laboratory Automation and Screening (SLAS) annual meeting February 5-7, in San Diego, California. At booth #532 BellBrook will exhibit the new AptaFluor SAH Methyltransferase Assay in addition to the Transcreener line of HTS assays. Three posters presented at the conference will
Read more
No Comments

Transcreener ADP Assay Aids in Discovery of RIPK2 Inhibitors for Autoinflammation

When the body responds to a bacterial pathogen, fragments of bacterial peptidoglycan alert a human host to the presence of a microbial invader. A receptor named NOD2 recognizes the peptidoglycans and sounds the alarm, initiating immune responses by causing the production of pro-inflammatory cytokines via NF-κB and MAP kinase pathways 1. In this manner, NOD2
Read more
No Comments

Doubling the Odds: Two-Pronged Strategy to Halt Cancer Cell Proliferation

It would be difficult to underestimate the importance of polo-like kinase 1 (Plk1) for cancer, given its influence on cell division. As one of five members of the Polo-like family of serine/threonine protein kinases in eukaryotic cells, Plk1 plays a multifaceted role in the cell cycle and thus controls cancer progression fueled by unchecked cell
Read more
No Comments

Newly Patented Aurora A Kinase Inhibitor a Promising Contender for Cancer Treatment

Aurora A Kinase in Cancer Drug Development Aurora A Kinase, along with -B and -C, are members of a family of serine/threonine protein kinases that play critical roles in coordinating mitosis, including establishment of the mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. The enzyme’s role
Read more
No Comments